from
$34.95
from
$34.95
from
$34.95
from
$34.95
In the latest large survey of 5,000 consumers, McKinsey found “proof of efficacy and scientific credibility” are now the top two most important purchase factors when evaluating non-prescription wellness products. Studies show that 82% of U.S. consumers now consider wellness a top priority of their everyday lives, with 65% relying on physicians as their most reliable source of recommendations for health, diet, exercise, and non-prescription wellness solutions. Healthcare providers (HCPs) need competent and reliable scientific evidence from rigorous clinical trials to confidently recommend wellness products. Yet, virtually no wellness brands have clinical trial data on their specific products, relying instead on marketing tactics, misleading labels and unverified claims.
With an unwavering commitment to science and patient trust, MDbio is one of the few brands able to meet the high evidence bar required by healthcare practitioners. Founded on robust science and transparency, MDbio has quickly become the leading clinically studied dietary supplement brand in the U.S. for health areas like sleep, mood, and pain. This commitment to patients is upheld through three core elements:
MDbio's model far exceeds regulatory requirements for dietary supplements and aligns more closely with pharmaceutical standards. By integrating best practices from both dietary supplement and pharmaceutical regulatory and business frameworks, MDbio has been able to rapidly develop and deliver safe, affordable, and effective solutions for practitioners and their patients.
The founding physicians of MDbio recognized several health issues that were commonly comorbid with their patients and impacted the trajectory of their health, regardless of their primary diagnosis. These issues – poor sleep, chronic stress, pain, and inflammation – all stemmed from, and contributed to, disruption of homeostasis.
A healthy body maintains homeostasis, but when overwhelmed by challenges, this balance can falter, leading to suboptimal wellness. Chronic stress, for instance, can lead to inflammation, disrupted sleep, anxious mood, and worsened pain. Similarly, chronic pain can lead to stress, mood disturbances, and disrupted sleep. Moreover, disruptions in sleep or mood can cause inflammation that can worsen the trajectory of a variety of chronic diseases. MDbio's products are designed to address these interconnected issues and break this vicious cycle of imbalance.
MDbio's product line offers safe and effective solutions for these key areas of concern: poor sleep, stress, and pain. Each product is formulated to help the body reestablish homeostasis and achieve optimal wellness.
As part of their commitment to science and patient trust, MDbio engaged the award-winning public benefit corporation Radicle Science to conduct large scale double-blind, randomized, placebo-controlled clinical trials on all of their products. The results are summarized below:
MDsleep
Radicle Science conducted a clinicaltrials.gov registered, IRB-approved, double-blind, randomized, placebo-controlled, decentralized clinical trial to assess the comparative effects of two multi-ingredient, melatonin-free supplements (Sleep A and Sleep B) on sleep disturbance relative to placebo. 620 U.S. adults with sleep disturbance were enrolled and randomly assigned to receive Sleep A, Sleep B, or placebo for 4-weeks. Sleep A and Sleep B both contained a mixture of several natural ingredients (including legal hemp derived cannabinoids, L-theanine, GABA, hops oil, and valerian oil) but differed in the amounts of those natural ingredients. Participants received their products via mail and completed all assessments virtually via a web app. Sleep disturbance was assessed at baseline and weekly using the U.S. Department of Health and Human Service’s Patient-Reported Outcomes Measurement Information System (PROMIS™) Sleep Disturbance SF 8A survey. In addition, the secondary outcomes of anxiety, stress, pain, and well-being were assessed using validated patient-reported outcome measures at baseline and weekly. A linear mixed-effects regression model was used to assess the change in health outcome score between active product groups and the placebo. Sleep A significantly improved sleep, anxiety, stress, and well-being compared to placebo. Sleep B did not improve any health parameter relative to placebo. There were no severe side effects in the study, and no significant difference in the frequency of side effects between placebo and Sleep A or Sleep B. Sleep A led to clinically meaningful improvements in sleep, anxiety, and stress in 57%, 60%, and 38% of participants, respectively. MDbio launched Sleep A as the MDsleep supplement.
MDrelief
The experience of pain varies widely among individuals due to biological, psychological, and social factors. Women, in particular, are more likely to report pain and be undertreated, and hormonal changes throughout a woman's life can further influence pain. Understanding how pain interventions impact different segments of the population is crucial for providing effective pain solutions. Radicle Science conducted a clinicaltrials.gov registered, IRB-approved, double-blind, randomized, placebo-controlled, decentralized clinical trial to assess the comparative effects of two multi-ingredient supplements (MB02 and MB03) on pain relative to placebo. 1160 U.S. adults experiencing pain were enrolled and randomly assigned to receive MB02, MB03, or placebo for 6-weeks. MB02 and MB03 both contained a mixture of several natural ingredients (including legal hemp derived cannabinoids, White Willow Bark Extract, Geranylgeraniol Oil, Frankincense Oil) but differed in the amounts of those natural ingredients. Participants received their products via mail and completed all assessments virtually via a web app. Pain interference, neuropathic pain, nociceptive pain, and pain intensity were assessed at baseline and weekly using the U.S. Department of Health and Human Service’s Patient-Reported Outcomes Measurement Information System (PROMIS™) and other validated patient-reported outcome measures (PROs). A longitudinal mixed-effects regression model was used to assess the change in health outcome score between active product groups and the placebo. In women below the average age of menopause (approximately age 50), MB03 significantly improved pain interference and pain intensity, relative to placebo. Averaged across all ages, genders, lifestyles, and pain diagnoses, MB03 led to clinically meaningful improvements in pain interference and pain intensity in 54% and 66% of participants, respectively. MB02 did not significantly improve any pain outcome relative to placebo. There were no severe side effects in the study, and no significant difference in the frequency of side effects was found between placebo and MB02 or MB03. MDbio launched MB03 as the MDrelief supplement.
MDcalm
Radicle Science conducted a clinicaltrials.gov registered, IRB-approved, double-blind, randomized, placebo-controlled, decentralized clinical trial to assess the comparative effects of two multi-ingredient supplements (MB01 and MB04) on feelings of anxiety relative to placebo. 1461 U.S. adults experiencing anxiety were enrolled and randomly assigned to receive MB01, MB04, or placebo for 6-weeks. MB01 and MB04 both contained a mixture of several natural ingredients (including legal hemp-derived cannabinoids, Lavender Oil, Peppermint Oil, Magnesium L-Threonate, Ashwagandha, and Reishi Mushroom) but differed in the amounts of those natural ingredients. Participants received their products via mail and completed all assessments virtually via a web app. Anxiety was assessed at baseline and weekly using the U.S. Department of Health and Human Service’s Patient-Reported Outcomes Measurement Information System (PROMIS™) Anxiety SF 8A survey. In addition, the secondary outcomes of stress, cognitive function, and sleep disturbance were assessed using validated patient-reported outcome measures at baseline and weekly. A longitudinal mixed-effects regression model was used to assess the change in health outcome score between active product groups and the placebo. MB01 significantly improved anxiety and sleep compared to placebo. MB04 did not improve any health parameter relative to placebo. There were no severe side effects in the study. However, participants assigned to the active arms were significantly more likely to report experiencing side effects than the placebo group. MB01 led to clinically meaningful improvements in anxiety and sleep disturbance in 77% and 66% of participants, respectively, and MDbio launched MB01 as the MDcalm supplement.
Conclusion
MDbio - The Doctors Brand™’s commitment to patient safety and health outcomes is reflected in their scientific and evidenced based approach to product development, clinical validation, and real world data monitoring. Across rigorous clinical trials studying several MDbio products over 3,000 diverse Americans for numerous health areas, MDbio has become the leading clinically proven dietary supplement brand in the U.S. U.S. patients finally have access to safe, affordable, and effective non-prescription products for key health areas that can improve their overall wellness.
Dr. Babak Larian, Clinical Chief at Cedars-Sinai Medical Center, is a renowned expert in minimally invasive head and neck surgery. Board-certified and active in global medical missions, he also oversees surgical operations at the La Peer Surgery Center and PathMD pathology laboratories.
Dr. Kia Michel, a globally acclaimed Urological Oncological Surgeon, founded the Comprehensive Urology Medical Group in Los Angeles, known for his expertise in robotic and minimally invasive therapies. Alongside his medical achievements, he contributes to businesses like La Peer Surgery Center, finding joy in nature and bringing smiles to loved ones.
Dr. Jamshidinia, a certified Foot and Ankle Surgeon and Fellow of the American College of Foot and Ankle Surgeons, founded Tower Foot & Ankle Surgery and co-founded successful enterprises, including La Peer Health Systems. His involvement in medical research and the cannabinoid medicine market, highlights his multifaceted contributions to the field.
Dr. Siamak Tabib, a Board-Certified Gastroenterologist in Beverly Hills, holds a medical degree from UCLA Geffen School of Medicine and serves as Assistant Clinical Professor at UCLA.
He actively contributes to research in digestive diseases, co- founding healthcare entities and advocating for adaptive sports opportunities through his advisory role at Angel City Sports.
Find Your Solution
